ResMed: Buy for Durable Growth and a Path Back to $280

Hook & thesis

ResMed (RMD) is a leader in sleep-disordered breathing devices and an increasingly important provider of residential care software. Recent results show the company growing revenue at about 11% year-over-year, while adjusted EPS continues accelerating. At roughly $220 per share and a market cap near $31.7 billion, ResMed presents an asymmetric trade: limited balance-sheet risk, recurring revenue tailwinds, and several near-term catalysts that can re-rate the stock back toward its prior highs around $280+.

My base trade: buy RMD at $220.02, keep a defined stop at $200.00, and target $280.00 over a long-term time frame (180 trading days). The setup offers a compelling reward-to-risk profile given healthy free cash flow generation ($1.65 billion trailing FCF), low leverage (debt/equity ~0.10), and an attractive valuation versus historical norms.

What the company does and why the market should care

ResMed designs and sells devices for diagnosing and treating sleep-disordered breathing (CPAP/BiPAP and related accessories), plus software and services for residential care. The business has two complementary engines:

• Sleep and Breathing Health: therapy devices and consumables that produce predictable, recurring revenue from replacement masks, filters, and accessories.
• Residential Care Software: a higher-margin, recurring SaaS-like franchise that expands lifetime value per customer and creates cross-sell opportunities.

The broad market matters: studies estimate close to a billion people globally have some form of sleep apnea; the respiratory care market is growing at mid-to-high single digits and homecare adoption is rising. ResMed benefits from both durable device demand and software-driven margin expansion.

Fundamentals and recent performance - the numbers that matter

• Current share price: $220.02 with a 52-week range of $180.27 - $284.87.
• Market cap: approximately $31.7 billion; enterprise value: about $30.92 billion.
• Recent quarterly results: revenue of about $1.42 billion in Q2 FY2026 (+11% YoY) with adjusted EPS of $2.81 beating consensus.
• Profitability and cash flow: trailing free cash flow ~$1.65 billion; return on equity ~23.1%; return on assets ~17.0%.
• Balance sheet: cash roughly $1.09 billion and modest leverage (debt/equity ~0.10).
• Valuation snapshot: reported P/E in the low-20s (~20.8 - 21.2 depending on source) and EV/EBITDA ~14.7.

Those numbers add up to a stable cash-generative business that can invest in R&D and tuck-in acquisitions (see Noctrix Health), pay a modest dividend (quarterly $0.66 per share), and buy back stock.

Valuation framing

At a market cap near $31.7 billion and a forward P/E in the low 20s, ResMed is trading below its recent five-year average multiple (analyst commentary points to a five-year average forward P/E around 29). The company is not cheap on an absolute basis - EV/sales of ~5.47 and EV/EBITDA ~14.65 imply the market expects steady top-line growth and healthy margins. But two factors argue for a re-rate:

• Organic growth remains solid: management expects high single-digit revenue growth with double-digit EPS growth, and recent results showed 11% revenue growth.
• Margin expansion and recurring revenue: software and consumables create predictable margin tailwinds and higher lifetime revenue per customer.

Put differently, ResMed looks like a high-quality growth business currently trading at a P/E that discounts some execution risk. If the company delivers consistent double-digit EPS growth and integrates recent acquisitions well, multiples could expand back toward historical averages.

Trade plan (actionable)

Rationale: Entering at $220.02 buys near the 50-day EMA (~$219.70) and not far from the stock's recent consolidation zone. The $200 stop caps downside to a level below the recent 52-week low midpoints and preserves capital in case of an adverse market shock. The $280 target is inside the stock's prior year high of $284.87 and represents a sensible upside if catalysts materialize and the market re-rates RMD toward its historical multiple.

Catalysts to drive the trade

• Continued organic growth and margin beats: another quarter of ~10%+ revenue growth and EPS beats would validate the bull case.
• Successful integration of acquisitions: the June acquisition of Noctrix Health for $340 million adds a neuromodulation therapy that can expand product breadth and cross-sell into ResMed’s installed base.
• Commercial wins and regulatory approvals: additional FDA clearances (e.g., AI-enabled device upgrades) and partnership announcements can accelerate adoption of higher-margin software offerings.
• Analyst upgrades and multiple expansion: If forward estimates hold and management raises targets, the P/E could rerate toward its historical averages.
• Short-interest dynamics: elevated short volume in recent sessions raises the probability of squeeze dynamics on favorable news or earnings beats.

Risks and counterarguments

Every trade has risk. Here are the primary risks that could invalidate or materially impair the thesis, and one counterargument worth considering:

• Reimbursement pressure: Medicare or other payor reimbursement changes for CPAP and related therapies could compress volumes and ASPs. Policy risk is non-trivial in medical devices and could reduce revenue growth.
• Competition and product substitution: New entrants, alternative therapies to CPAP, or improved oral appliances could slow device replacement cycles and reduce consumables revenue.
• Execution on software monetization: Residential care software has attractive margin potential, but scaling enterprise sales and retention is different from device sales. Slower adoption or higher churn would reduce the valuation premium.
• Macroeconomic and market risk: A broader risk-off market or recession would likely compress high-quality growth multiples and could push the stock well below the $200 stop.
• M&A integration risk: The Noctrix acquisition adds new technology but could distract management or fail to deliver expected synergies if integration missteps occur.

Counterargument: One could argue RMD already prices in its quality - the stock is not a deep value play, and forward multiples in the low-20s already assume steady execution. If growth slows toward low single digits, the valuation could reprice materially lower and the stock could revisit the $180s. This is why a defined stop and size discipline matter.

What would change my mind

I would materially change my stance if any of the following occurred:

• Management guided to a sustained revenue slowdown (below mid-single-digit growth) or reduced free cash flow guidance.
• Clear reimbursement cuts from Medicare or a major payor that meaningfully impacts device adoption or ASPs.
• Major safety or regulatory issues affecting core devices that lead to recalls or materially higher warranty/repair costs.

If none of those happen and ResMed continues to deliver mid-to-high single-digit revenue growth with double-digit EPS expansion, I would look to add to the position on pullbacks and hold above the stop with an eye toward the $280 target within the 180 trading day window.

Bottom line

ResMed is a high-quality med-tech compounder with recurring revenue, solid free cash flow, and a low-leverage balance sheet. At $220.02 the risk/reward looks reasonable: downside is limited by a well-capitalized balance sheet and an established recurring revenue base, while upside is supported by margin expansion, software monetization, tuck-in M&A, favorable market dynamics in respiratory care, and the potential for multiple re-expansion. The trade is a long-term tactical buy with a clear stop at $200.00 and a target at $280.00 over the next 180 trading days.

Key watch items after entry

• Quarterly results vs. consensus: focus on recurring revenue mix, consumables growth, and guidance.
• Integration updates on Noctrix and any incremental regulatory clearances.
• Short-interest and short-volume trends around earnings and product announcements.